2021 Global Pharmaceuticals, Biotech and Diagnostics Valuation and Option Bids Analysis Report: Full Access to Records Available for Over 1,300 Bids – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The report “Global Option and Evaluation Partnership Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021” has been added to from ResearchAndMarkets.com offer.

The Global Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides full access to available records for over 1,300 option and evaluation agreements, including contract documents where available .

This report focuses on option and valuation agreements and clauses in broader agreements between big pharma-big pharma, big pharma-small business and small business-small business, providing a detailed overview of all such transactions.

There are two main forms of agreement terms that allow a party to an agreement to obtain rights to an asset subject to a future event, namely option and valuation.

Evaluation agreements allow a party to the agreement to obtain rights to a technology or compound, subject to a period of time to evaluate the quality, scope and applicability of the technology to its purpose. final. Normally the technology is early stage and/or unproven and the partner company wants to evaluate the technology as part of the due diligence process before signing a long-term license agreement.

Evaluation agreements have been a mainstay of technology licensing since the early days. An option agreement differs in that the option often forms part of an agreement already entered into by the parties, providing the party with the right to option to retain or extend certain rights to the technology already associated.

Option agreements are becoming increasingly popular because they create additional flexibility in an agreement for additional rights that the parties do not wish to commit to at the start of the agreement.

The report provides a detailed understanding and analysis of how and why companies enter into option and valuation agreements. The majority of agreements are multi-component, with the licensor retaining either an option right or an evaluation right over the product resulting from the research collaboration. There are also many pure option and evaluation agreements in which the originator of the product engages a partner in order to advance the product or compound to a point where the licensee might seek to enter into a licensing agreement. .

Understanding the flexibility of the terms of agreements negotiated by a potential partner provides essential insight into the negotiation process in terms of what you can expect to accomplish when negotiating the terms. While many small businesses will be looking for details on payment clauses, the devil is in the details in terms of triggering payments – contract documents provide this information where press releases and databases do not. .

This report contains a complete list of all Option and Valuation offers announced since 2014, as recorded in the Offers and Alliances database, including financial terms when available, as well as links to online copies of actual option contract and valuation documents as submitted to the Securities Exchange Commission by firms and their partners.

Report scope

The 2014-2021 global pharmaceutical, biotechnology and diagnostics option and evaluation partnership terms and agreements include:

  • Trends in option and valuation agreements in the biopharmaceutical industry since 2014

  • Analysis of the option and the structure of the evaluation agreement

  • Case studies of real options and valuation offers

  • Access to over 1,300 options and valuation records

  • The leader in option trading and value valuation since 2014

  • Most active options and valuation traders since 2014

  • Key Option and Evaluation Partnership Resources

Available offers are listed by:

  • A-Z company

  • Face value

  • Stage of development at signing

  • Therapeutic space

  • Type of technology

The analysis of the actual contractual agreements makes it possible to evaluate the following elements:

  • What specific rights are granted or optional?

  • What is actually granted by the agreement to the partner company?

  • What exclusivity is granted?

  • What is the payment structure for the transaction?

  • How are sales and payments audited?

  • What is the duration of the agreement?

  • How are the main terms of the agreement defined?

  • How are IPRs managed and owned?

  • Who is responsible for marketing?

  • Who is responsible for development, supply and manufacturing?

  • How are confidentiality and publication managed?

  • How to settle disputes?

  • Under what conditions can the agreement be terminated?

  • What happens if the owner changes?

  • What sub-licensing and sub-contracting arrangements have been agreed upon?

  • What boilerplate clauses does the company insist on?

  • What boilerplate clauses seem to differ from one partner to another or from one type of transaction to another?

  • What jurisdiction does the company insist on for contract law?

Main topics covered:

Abstract

Chapter 1 Introduction

Chapter 2 – Trends in Options Trading and Valuation

2.1. introduction

2.2. Difference Between Option and Appraisal Agreements

2.2.1. Option Agreement Types

2.3. Trends in options and valuation offerings since 2014

2.3.1. Options and valuation trades by year since 2014

2.3.2. Options and valuation transactions by development stage since 2014

2.3.3. Options and valuation trades by industry since 2014

2.3.4. Options trading and valuation by therapeutic area since 2014

2.3.5. Options and valuation trades by technology type since 2014

2.3.6. Most active options and valuations trading since 2014

2.4. Option-Based Agreements

2.4.1. Option-Based Agreement Attributes

2.4.2. Reasons for entering into an option-based transaction

2.4.3. Acceptance of the exercise of the option

2.4.4.The future of options trading

2.5. Co-promotion options

2.5.1. Attributes of co-promotion in multi-component offers

2.5.2. Reasons to include co-promotion options in a deal

2.5.3. Use of co-promotion rights

2.5.4. Co-promotion rights as bargaining chips

2.5.5. The future of co-promotion in multi-component deals

2.6. Business acquisition options

2.6.1. Case study 1: Cephalon – Ception

2.6.2. Case Study 2: Endo – Indevus

2.6.3. The future of the vesting option

Chapter 3 – Overview of Option Bid Structure and Valuation

3.1. introduction

3.2. Structure of Option and Valuation Agreement

3.2. Sample Assessment Agreements

3.2.1.a. Case Study 3: Idenix Pharmaceuticals – Janssen Pharmaceuticals

3.3. Structure of the option agreement

3.3.1. Examples of Option Agreements

3.3.1.a. Licensing option

Case Study 4: Biogen Idec – Isis Pharmaceuticals

3.3.1.b. Ability to extend/expand applications/territories

Case study 5: Novartis – Prometheus

3.3.1.c. Possibility of financing

Case Study 6: Amarantus BioSciences – Power3 Medical Products

3.3.1.d. Opportunity to co-promote

Case Study 7: Teva – OncoGenex Pharmaceuticals

3.3.1.e. Manufacturing/supply option

Case Study 8: NPS Allelix – Nycomed

3.4. Option to acquire agreement structure

3.4.1. Examples of vesting option clauses

3.4.1.a. Case Study 9: ViroPharma – Meritage Pharma

3.4.1.b. Case Study 10: Nuvasive – Orthobiology Progentix

Chapter 4 – Main option and valuation contracts

4.1. introduction

4.2. Top Option and Valuation Offerings by Value

Chapter 5 – Top 25 Most Active Options and Valuation Traders

5.1. introduction

5.2. Top 25 Most Active Options and Valuation Traders

Chapter 6 – Directory of Option and Valuation Contracts

6.1. introduction

6.2. Option and Valuation deals with contracts since 2014

Appendices

Appendix 1 – Options and Valuation Trading by AZ Companies

Appendix 2 – Options and valuation trades by industry

Appendix 3 – Options and Valuation Transactions by Stage of Development

Appendix 4 – Option Purchase Decision and Valuation by Therapeutic Area

Appendix 5 – Options Trading and Valuation by Technology Type

For more information about this report visit https://www.researchandmarkets.com/r/97de1w

Comments are closed.